Adil Daud

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi request reprint Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study
    Adil Daud
    Cutaneous Oncology, Experimental Therapeutics, and Gastrointestinal Oncology Programs, H Lee Moffitt Cancer Center, Tampa, Florida 33612, USA
    Clin Cancer Res 11:3009-16. 2005
  2. ncbi request reprint Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
    George R Simon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:4645-51. 2006
  3. doi request reprint Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
    Steven E Finkelstein
    Immunotherapy Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunother 33:817-27. 2010
  4. ncbi request reprint The Src signaling pathway: a potential target in melanoma and other malignancies
    Jade Homsi
    Cutaneous Therapeutic Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, USA
    Expert Opin Ther Targets 11:91-100. 2007
  5. ncbi request reprint Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
    Pamela Munster
    Experimental Therapeutics, Breast Medical Oncology Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    J Clin Oncol 25:1979-85. 2007
  6. ncbi request reprint Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma
    Eric H Jensen
    Department of Interdisciplinary Oncology, Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Stabile Research Building, Room 22043, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Ann Surg Oncol 14:1416-23. 2007
  7. ncbi request reprint Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
    Guilian Niu
    Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Department of Oncology, University of South Florida College of Medicine, Tampa, Florida, FL 33612, USA
    Oncogene 21:7001-10. 2002
  8. ncbi request reprint Cutaneous melanoma: prognostic factors
    Jade Homsi
    Cutaneous Oncology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 12:223-9. 2005
  9. ncbi request reprint Melanoma
    Alan N Houghton
    J Natl Compr Canc Netw 4:666-84. 2006
  10. ncbi request reprint Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model
    Loree Heller
    Department of Medical Microbiology and Immunology, University of South Florida, Tampa 33612, USA
    Clin Cancer Res 12:3177-83. 2006

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study
    Adil Daud
    Cutaneous Oncology, Experimental Therapeutics, and Gastrointestinal Oncology Programs, H Lee Moffitt Cancer Center, Tampa, Florida 33612, USA
    Clin Cancer Res 11:3009-16. 2005
    ..Patients were biopsied to determine topoisomerase expression at baseline and response to therapy...
  2. ncbi request reprint Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
    George R Simon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:4645-51. 2006
    ..In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability...
  3. doi request reprint Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
    Steven E Finkelstein
    Immunotherapy Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunother 33:817-27. 2010
    ..Pretreatment assessment of DC phenotypic or maturational status may be a starting point to predicting response to high-dose IL-2 cytokine immunotherapy in patients with melanoma and kidney cancer...
  4. ncbi request reprint The Src signaling pathway: a potential target in melanoma and other malignancies
    Jade Homsi
    Cutaneous Therapeutic Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, USA
    Expert Opin Ther Targets 11:91-100. 2007
    ..Cumulatively, these data mark Src signaling as attractive therapeutic targets in melanoma. Studies are currently underway with novel Src inhibitors in melanoma and in other tumor types...
  5. ncbi request reprint Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
    Pamela Munster
    Experimental Therapeutics, Breast Medical Oncology Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    J Clin Oncol 25:1979-85. 2007
    ....
  6. ncbi request reprint Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma
    Eric H Jensen
    Department of Interdisciplinary Oncology, Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Stabile Research Building, Room 22043, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Ann Surg Oncol 14:1416-23. 2007
    ..We used cDNA microarray to evaluate pro-apoptotic gene expression comparing normal skin to melanoma (thin and thick), nodal disease and distant metastases...
  7. ncbi request reprint Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
    Guilian Niu
    Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Department of Oncology, University of South Florida College of Medicine, Tampa, Florida, FL 33612, USA
    Oncogene 21:7001-10. 2002
    ..These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells...
  8. ncbi request reprint Cutaneous melanoma: prognostic factors
    Jade Homsi
    Cutaneous Oncology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 12:223-9. 2005
    ..Recent data have changed our views of prognostic factors in cutaneous melanoma. While some newer methods have yielded better prognostic information, some insights have evolved as a result of large-scale population-based analyses...
  9. ncbi request reprint Melanoma
    Alan N Houghton
    J Natl Compr Canc Netw 4:666-84. 2006
  10. ncbi request reprint Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model
    Loree Heller
    Department of Medical Microbiology and Immunology, University of South Florida, Tampa 33612, USA
    Clin Cancer Res 12:3177-83. 2006
    ..To translate this observation to the clinic, an evaluation of toxicity was done in the mouse model...
  11. ncbi request reprint A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Carol Aghajanian
    The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2505-11. 2002
    ..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies...